Pharma Mar SA
ISIN ES0169501022
|WKN A2P9YT
Overview
Description
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Spain
Financials
Key metrics
| Market capitalisation, EUR | 1,348.44 m |
| EPS, EUR | 1.48 |
| P/B ratio | 6.24 |
| P/E ratio | 49.68 |
| Dividend yield | 0.88% |
Income statement (2024)
| Revenue, EUR | 174.86 m |
| Net income, EUR | 26.13 m |
| Profit margin | 14.94% |
What ETF is Pharma Mar SA in?
There are 25 ETFs which contain Pharma Mar SA. All of these ETFs are listed in the table below. The ETF with the largest weighting of Pharma Mar SA is the L&G Pharma Breakthrough UCITS ETF.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
